Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02238496
Title Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Andrew Lassman
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.